[Bioinformatic analysis of CCND2 expression in papillary thyroid carcinoma and its impact on immune infiltration].

[OBJECTIVE] To investigate cyclin D2 (CCND2) expression in papillary thyroid carcinoma (PTC) and its association with the clinicopathological features.

[METHODS] The public databases TCGA, TIMER 2.0 and UALCAN were used to explore CCND2 expression level in PTC and adjacent tissues, and its diagnostic value for PTC was analyzed using ROC curves. GO enrichment analysis of CCND2-related differentially expressed genes (DEGs) in PTC was performed, and tumor immune infiltration of CCND2 in thyroid cancer was analyzed using TIMER database and CIBERSORT data source. RT-qPCR and Western blot were used to detect CCND2 expression in normal human thyroid cell line Nthy-ori-3-1 and human PTC cell lines TPC-1 and BCPAP. CCND2 expression was also detected in clinical specimens of PTC and adjacent tissues by immunohistochemistry, and its correlation with clinicopathological features of the patients were analyzed.

[RESULTS] Informatic analysis revealed significantly higher CCND2 mRNA expression in thyroid cancer than in the adjacent tissues ( < 0.001) in close correlation with tumor stage, gender, age, pathological subtype, and lymph node involvement ( < 0.05). ROC curve analysis showed that at the cutoff value of 4.983, the diagnostic sensitivity, specificity, and accuracy of CCND2 expression for PTC was 83.6%, 94.9%, and 78.5%, respectively. CCND2 expression was positively correlated with B cells, CD4 T cells, and macrophages ( < 0.001) and negatively with CD8 T cells ( < 0.01), and also correlated with memory B-cell infiltration, CD4 T-cell memory activation, M2 macrophages, resting mast cells, and mast cell activation ( < 0.05). RT-qPCR, Western blot and immunohistochemistry showed significantly higher CCND2 expression in the PTC cells than in Nthy-ori-3-1 cells ( < 0.01) and also in clinical PTC tissues than in the adjacent tissues ( < 0.05) in correlation with tumor size, lymph node metastasis and TNM stage ( < 0.05).

[CONCLUSION] CCND2 overexpression is closely correlated with tumor progression and immune cell infiltration in PTC patients..